Liquid Biopsy Predicts Esophageal Cancer Patient Response to Treatment

Liquid Biopsy Predicts Esophageal Cancer Patient Response to Treatment

December 10, 2020 03:58 PM Eastern Standard Time

ROCKVILLE, Md.–(BUSINESS WIRE)–Creatv MicroTech, a privately-held biotechnology company has pioneered a blood test to predict treatment response in patients with newly diagnosed Stage I-III esophageal cancer (EC) treated with chemoradiation therapy (CRT). The results were published in the Journal of Translational Medicine.

URL link to full story
https://www.businesswire.com/news/home/20201210006080/en
Media Contact
Ron Baker
301-785-5185
Comments are closed.